Stocktoria
Rani Therapeutics Holdings, Inc. RANI
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-07-30
Rani Therapeutics Holdings, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.6M | $1.0M | $0 | $0 | $2.7M | $462,000 |
| R&D expense | $20.2M | $26.7M | $39.6M | $36.6M | $26.5M | $12.0M |
| Operating income | -$38.3M | -$53.3M | -$66.1M | -$63.5M | -$51.6M | -$16.5M |
| Interest expense | $2.9M | $5.0M | $5.1M | $1.1M | $466,000 | $124,000 |
| Income tax | $0 | $0 | $0 | $70,000 | $41,000 | $35,000 |
| Net income | -$29.7M | -$30.0M | -$34.0M | -$30.6M | -$8.3M | — |
| EPS (diluted) | $-0.45 | $-1.05 | $-1.33 | $-1.28 | $-0.43 | — |
| Operating cash flow | -$18.7M | -$35.5M | -$51.2M | -$46.5M | -$32.2M | -$15.0M |
| Free cash flow | -$18.8M | -$35.8M | -$52.5M | -$48.1M | -$32.8M | -$16.2M |
| Cash & equivalents | $18.6M | $3.8M | $5.9M | $27.0M | $117.5M | $73.1M |
| Total assets | $58.6M | $36.6M | $57.9M | $108.0M | $124.2M | $79.4M |
| Total liabilities | $17.1M | $33.1M | $32.5M | $34.0M | $2.6M | $8.0M |
| Shareholders' equity | $41.5M | $3.5M | $25.4M | $74.0M | $121.6M | -$113.3M |
Growth · year-over-year · Revenue CAGR 28.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +58.9% | — | — | -100.0% | +488.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.